Pacific Heights Asset Management LLC reduced its position in shares of Amgen Inc. (NASDAQ:AMGN) by 1.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 108,000 shares of the medical research company’s stock after selling 2,000 shares during the period. Amgen accounts for approximately 1.5% of Pacific Heights Asset Management LLC’s investment portfolio, making the stock its 18th largest position. Pacific Heights Asset Management LLC’s holdings in Amgen were worth $16,432,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Oakworth Capital Inc. increased its position in shares of Amgen by 16.6% in the second quarter. Oakworth Capital Inc. now owns 701 shares of the medical research company’s stock valued at $111,000 after buying an additional 100 shares during the period. Delta Asset Management LLC TN increased its position in shares of Amgen by 9.1% in the second quarter. Delta Asset Management LLC TN now owns 1,020 shares of the medical research company’s stock valued at $155,000 after buying an additional 85 shares during the period. Capital Advisors Ltd. LLC increased its position in shares of Amgen by 0.6% in the second quarter. Capital Advisors Ltd. LLC now owns 1,078 shares of the medical research company’s stock valued at $164,000 after buying an additional 6 shares during the period. Vigilant Capital Management LLC increased its position in shares of Amgen by 2.6% in the second quarter. Vigilant Capital Management LLC now owns 1,283 shares of the medical research company’s stock valued at $195,000 after buying an additional 33 shares during the period. Finally, Calamos Wealth Management LLC acquired a new position in shares of Amgen during the second quarter valued at $202,000. Institutional investors and hedge funds own 79.15% of the company’s stock.

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Amgen Inc. (NASDAQ:AMGN) traded up 0.25% on Thursday, reaching $164.29. The company’s stock had a trading volume of 2,369,996 shares. The firm has a 50 day moving average price of $170.01 and a 200 day moving average price of $162.16. The stock has a market capitalization of $122.95 billion, a P/E ratio of 16.81 and a beta of 0.94. Amgen Inc. has a 52 week low of $139.02 and a 52 week high of $176.85.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Wednesday, July 27th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.74 by $0.10. Amgen had a return on equity of 29.30% and a net margin of 33.07%. The firm earned $5.69 billion during the quarter, compared to the consensus estimate of $5.58 billion. During the same period in the previous year, the firm posted $2.57 EPS. The company’s quarterly revenue was up 5.9% compared to the same quarter last year. On average, equities analysts anticipate that Amgen Inc. will post $11.35 EPS for the current year.

Several analysts have weighed in on AMGN shares. BMO Capital Markets reiterated an “outperform” rating and set a $190.00 price target on shares of Amgen in a research note on Thursday, September 22nd. Jefferies Group reiterated a “buy” rating and set a $198.00 price target on shares of Amgen in a research note on Tuesday, August 23rd. Vetr upgraded Amgen from a “sell” rating to a “hold” rating and set a $171.34 price target on the stock in a research note on Wednesday, August 3rd. Leerink Swann reiterated a “hold” rating on shares of Amgen in a research note on Saturday, September 17th. Finally, Credit Suisse Group AG set a $206.00 price target on Amgen and gave the company a “buy” rating in a research note on Saturday, September 17th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and twelve have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $184.94.

In related news, VP Annette Louise Such sold 3,000 shares of Amgen stock in a transaction that occurred on Tuesday, August 2nd. The stock was sold at an average price of $174.59, for a total transaction of $523,770.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.20% of the company’s stock.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).

5 Day Chart for NASDAQ:AMGN

Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.